AMGN
Amgen Inc. Common Stock
$439.40
장중 · Vol 121.2K · 52주 $269.77–$447.03 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $427.40 · Aug 31, 2026
AMGN 가격 추세
종가
$427.40
시가
$428.59
고가
$428.59
저가
$426.66
30초 브리핑
AMGN 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 96%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 17.6배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.2배
거래량은 최근 평균 범위입니다.
2026-11-03
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
AMGN 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
One Amgen Center Drive · Thousand Oaks, CA, United States · 직원 31,500명
시가총액
$232.41B
Trailing P/E
26.9
최근 12개월 이익 기준
Forward P/E
17.6
이익 증가 기대 반영
EPS (TTM)
$15.99
배당 수익률
2.33%
배당성향
60.9%
베타
0.41
시장보다 방어적
ROE
91.5%
P/B
19.88
EV/EBITDA
16.0
52주 범위
$269.77 – $447.03
현재 위치 96%
거래량
2.11M
20일 평균 1.83M · 1.2배
애널리스트 의견
매수 41%
총 34명 · 0m
DITM LEAPS Analysis
AMGN 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN280121C00260000 | 1/21/28 · 1.4Y | $260.00 | $180.25 | 2.2x | 0.9197 | 5.8% | 2.50% | 41.38% | 20 | 82.69 | |
| AMGN280121C00270000 | 1/21/28 · 1.4Y | $270.00 | $172.00 | 2.3x | 0.9085 | 7.0% | 2.91% | 41.10% | 17 | 80.39 | |
| AMGN280121C00280000 | 1/21/28 · 1.4Y | $280.00 | $163.75 | 2.4x | 0.8987 | 8.5% | 2.75% | 40.17% | 8 | 78.00 | |
| AMGN280121C00290000 | 1/21/28 · 1.4Y | $290.00 | $155.75 | 2.5x | 0.8870 | 10.2% | 2.89% | 39.60% | 37 | 77.38 | |
| AMGN280121C00220000 | 1/21/28 · 1.4Y | $220.00 | $228.25 | 1.7x | 0.9196 | 8.1% | 1.97% | 58.90% | 4 | 76.01 | |
| AMGN280121C00300000 | 1/21/28 · 1.4Y | $300.00 | $148.25 | 2.5x | 0.8734 | 12.4% | 3.04% | 39.33% | 52 | 75.06 | |
| AMGN280121C00240000 | 1/21/28 · 1.4Y | $240.00 | $210.75 | 1.9x | 0.9055 | 9.9% | 2.14% | 55.53% | 8 | 74.41 | |
| AMGN280121C00310000 | 1/21/28 · 1.4Y | $310.00 | $140.75 | 2.6x | 0.8596 | 14.8% | 3.20% | 38.90% | 69 | 72.65 | |
| AMGN280121C00320000 | 1/21/28 · 1.4Y | $320.00 | $133.25 | 2.7x | 0.8456 | 17.5% | 3.38% | 38.34% | 99 | 70.24 | |
| AMGN280121C00330000 | 1/21/28 · 1.4Y | $330.00 | $126.25 | 2.8x | 0.8299 | 20.9% | 3.56% | 38.01% | 41 | 66.07 | |
| AMGN270917C00330000 | 9/17/27 · 1.0Y | $330.00 | $120.25 | 3.0x | 0.8367 | 16.9% | 3.74% | 38.99% | 1 | 63.65 | |
| AMGN280121C00340000 | 1/21/28 · 1.4Y | $340.00 | $119.25 | 2.9x | 0.8139 | 24.6% | 3.77% | 37.56% | 89 | 63.44 | |
| AMGN280121C00350000 | 1/21/28 · 1.4Y | $350.00 | $112.50 | 3.0x | 0.7976 | 29.0% | 3.56% | 36.98% | 74 | 59.73 | |
| AMGN280121C00360000 | 1/21/28 · 1.4Y | $360.00 | $106.00 | 3.2x | 0.7799 | 34.1% | 3.77% | 36.61% | 79 | 55.66 | |
| AMGN270917C00360000 | 9/17/27 · 1.0Y | $360.00 | $98.50 | 3.4x | 0.7832 | 29.1% | 4.06% | 36.97% | 2 | 53.46 | |
| AMGN280121C00370000 | 1/21/28 · 1.4Y | $370.00 | $99.75 | 3.3x | 0.7611 | 40.0% | 4.51% | 36.40% | 110 | 51.19 |
재무제표
AMGN 연간 손익·현금흐름·재무상태
매출 성장률
+10.0%
최근 연간 YoY
EPS 성장률
+88.2%
최근 연간 YoY
영업이익률
24.7%
최근 연간
FCF 마진
22.0%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $36.75B+10.0% | $33.42B+18.6% | $28.19B+7.1% | $26.32B |
| 매출총이익 | $24.71B+20.2% | $20.57B+4.2% | $19.74B-0.9% | $19.92B |
| 영업이익 | $9.08B+25.1% | $7.26B-8.1% | $7.90B-17.4% | $9.57B |
| 순이익 | $7.71B+88.5% | $4.09B-39.1% | $6.72B+2.5% | $6.55B |
| 희석 EPS | $14.23+88.2% | $7.56-39.5% | $12.49+3.1% | $12.11 |
| EBITDA | $16.90B+26.5% | $13.36B-9.8% | $14.80B+21.6% | $12.17B |
| 영업현금흐름 | $9.96B-13.3% | $11.49B+35.6% | $8.47B-12.9% | $9.72B |
| 잉여현금흐름 | $8.10B-22.1% | $10.39B+41.2% | $7.36B-16.2% | $8.79B |
| 총자산 | $90.59B-1.4% | $91.84B-5.5% | $97.15B+49.2% | $65.12B |
| 총부채 | $54.60B-9.1% | $60.10B-7.0% | $64.61B+65.9% | $38.95B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
AMGN 실적·배당 일정
매출 하단
$9.80B
EPS 하단
$5.48
매출 상단
$10.27B
배당 지급일
2026-09-11
D-10
실적 발표일
2026-11-03
D-63
EPS 상단
$6.16
매출 컨센서스
$10.04B
EPS 컨센서스
$5.78
배당락일
2026-08-21
11일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 21, 2026 | $2.5200 |
| May 15, 2026 | $2.5200 |
| Feb 13, 2026 | $2.5200 |
| Nov 21, 2025 | $2.3800 |
| Aug 22, 2025 | $2.3800 |
| May 16, 2025 | $2.3800 |
| Feb 14, 2025 | $2.3800 |
| Nov 18, 2024 | $2.2500 |
뉴스
AMGN 관련 최신 기사
제품·기술One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
Investor's Business Daily · Aug 31, 2026
제품·기술How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
Barchart · Aug 31, 2026
실적Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Motley Fool · Aug 29, 2026
일반AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?
Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...
Simply Wall St. · Aug 28, 2026
일반Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Trefis · Aug 28, 2026
일반Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
Investor's Business Daily · Aug 27, 2026
- 제품·기술
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
Tezspire met both primary endpoints in an esophagitis trial, but AstraZeneca shares slipped roughly 0.6% Thursday.
GuruFocus.com · Aug 27, 2026
일반AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Zacks · Aug 27, 2026
제품·기술1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
StockStory · Aug 27, 2026
- 일반
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
BioPharma Dive · Aug 27, 2026
홀더
AMGN 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
85.1%
기관 보유 (유동주식)
85.3%
내부자 보유
0.2%
기관 수
3,992
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 49.36M | $21.22B | 9.1% | 4.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 35.25M | $15.15B | 6.5% | 0.7% | Jun 30, 2026 |
| State Street Corporation | 30.56M | $13.14B | 5.7% | 0.0% | Jun 30, 2026 |
| Capital World Investors | 29.08M | $12.50B | 5.4% | -0.7% | Jun 30, 2026 |
| Invesco Ltd. | 16.32M | $7.02B | 3.0% | 2.7% | Jun 30, 2026 |
| Geode Capital Management, LLC | 15.70M | $6.75B | 2.9% | 1.7% | Jun 30, 2026 |
| Charles Schwab Investment Management, Inc. | 15.03M | $6.46B | 2.8% | 17.7% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 14.85M | $6.39B | 2.8% | 1.6% | Jun 30, 2026 |
| Morgan Stanley | 13.65M | $5.87B | 2.5% | -13.8% | Jun 30, 2026 |
| Wells Fargo & Company | 7.24M | $3.11B | 1.3% | 2.1% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.